Ireland· IE-PA-EU/1/18/1348/001
Mulpleo
A lusutrombopag product containing lusutrombopag, registered in Ireland by Shionogi B.V.. The same ATC class is registered in 7 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Lusutrombopag is registered in 7 of 19 countries.
Countries holding a registration under ATC B02BX07 (lusutrombopag), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 4 of them publish a price we can compare per daily dose
Lusutrombopag · ATC B02BX07
7 / 19 countries
- Belgiumprice
- Finlandprice
- Ireland
- Japan
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- LUSUTROMBOPAG
- Manufacturer
- Shionogi B.V.
- Country
- Ireland (IE)
- ATC code
- B02BX07
- ATC class
- Lusutrombopag
- Defined daily dose
- 3 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- July 13, 2026
Packs & prices · 1
- ie_pa_numberEU/1/18/1348/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
164 interactions on record for lusutrombopag.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lusutrombopag · interactions on record
164 records
- 2 severe
- 162 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- RolapitantA04AD14moderate
- FidaxomicinA07AA12moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lusutrombopag in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b4e594bc-c6dd-41fa-bf20-0265b50ac909 GET /v1/drugs/b4e594bc-c6dd-41fa-bf20-0265b50ac909?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"B02BX07"
],
"strength": null,
"pa_number": "EU/1/18/1348/001",
"substances": [
"LUSUTROMBOPAG"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "18/02/2019",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about lusutrombopag.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.